Intercept Plasma System: Phase III

Interim data from the first 9 patients with congenital blood clotting deficiencies in CERS's 34-patient Phase IIIa trial showed that Intercept-treated

Read the full 214 word article

How to gain access

Continue reading with a
two-week free trial.